ESMO Asia 2019 - ESMO Asia Congress
Nov 22 - Nov 24, 2019 | SingaporeSingapore
LARVOL is not affiliated with ESMO Asia Congress and all trademarks, logos, and brand names are property of their respective owners
Showing 112 abstracts linked to Trials
Phase III KEYNOTE-048 study of first-line pembrolizumab for recurrent/metastatic head and neck squamous cell carcinoma: Asia vs non-Asia subgroup analysis
Subgroup analysis of IMpassion130: Atezolizumab + nab-paclitaxel (nab-P) in patients (pts) with advanced triple-negative breast cancer (TNBC) in Asian countries
Phase III PAOLA-1/ENGOT-ov25 trial: Olaparib plus bevacizumab (bev) as maintenance therapy in patients (pts) with newly diagnosed, advanced ovarian cancer (OC) treated with platinum-based chemotherapy (PCh) plus bev
Randomised efficacy and safety results for atezolizumab (Atezo) + bevacizumab (Bev) in patients (pts) with previously untreated, unresectable hepatocellular carcinoma (HCC)
Trastuzumab emtansine (T-DM1) vs trastuzumab (H) in Chinese patients (pts) with residual invasive disease after neoadjuvant chemotherapy for HER2-positive breast cancer (BC) in the phase III KATHERINE study
Patient-centred outcomes with maintenance olaparib in newly diagnosed patients with advanced ovarian cancer (OC) and a BRCA mutation in the phase III SOLO1 trial to support the clinical benefit of prolongation of progression-free survival (PFS)
Keynote-407 China Extension study: Pembrolizumab (pembro) plus chemotherapy in Chinese patients with metastatic squamous NSCLC
TATTON expansion cohorts: A phase Ib study of osimertinib plus savolitinib in patients (pts) with EGFR-mutant, MET-positive NSCLC following disease progression on a prior EGFR-TKI
Efficacy and safety of first-line durvalumab (D) ± tremelimumab (T) vs chemotherapy (CT) in Asian patients with metastatic NSCLC: Results from MYSTIC
Tepotinib in NSCLC patients harboring METex14 skipping: Cohort A of phase II VISION study
Longitudinal circulating tumour DNA (ctDNA) monitoring for early detection of disease progression and resistance in advanced NSCLC in FLAURA
Development and validation of a risk model integrating plasma Epstein-Barr virus DNA (EBV DNA) level and TNM stage for stratification of nasopharyngeal cancer (NPC) to adjuvant therapy
Talazoparib (TALA) vs physician’s choice of chemotherapy (PCT) in Asian patients (Pts) with HER2- advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCA1/2mut): Data from phase III EMBRACA
IMbrave150: Efficacy and safety results from a ph III study evaluating atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (Sor) as first treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC)
Tepotinib plus gefitinib in patients with MET-amplified EGFR-mutant NSCLC: Long-term outcomes of the INSIGHT study